Sonic Incytes Medical Corp. is pleased to host a live educational webinar on The Role of Next-Gen Non-Invasive Tests (NITs) in NAFLD/NASH. Join presenter Dr. Read more
Sonic Incytes is proud to expand its collaboration with key centers of clinical excellence in chronic liver disease in North America to continue evaluating its Read more
Sonic Incytes Medical Corp. is pleased to present its breakthrough liver health assessment solution, VelacurTM, at the Digital Medicine & Medtech Showcase 2021, part of Read more
At the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting 2020, Sonic Incytes presented the results of its clinical trial using Read more
Sonic Incytes Medical Corporation is pleased to announce the US commercial release of VelacurTM, the world’s first handheld 3D liver health assessment tool with diagnostic accuracy comparable to Magnetic Resonance Imaging (MRI).
Genome BC is pleased to announce $1 million in funding to Sonic Incytes Medical Corp., completing the company’s seed financing round of over CDN$3.5 million supported by institutional investors, angel funds and private individuals.
Sonic Incytes Medical Corp. is pleased to announce it has been selected to participate in the Canadian Technology Accelerator (CTA) 2020 program, along with 10 other promising start-ups in tech and life sciences from across Canada.
Poised for success with its breakthrough, handheld ultrasound solution for assessing and monitoring chronic liver disease, Sonic Incytes Medical Corp. has been named a top technology company in the 18th Annual “Ready to Rocket” list published by Rocket Builders today.